Hematologic Oncology Treatment Center

December 5–8, 2020
Virtual Meeting

Dana-Farber at ASH 2020

As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 62nd Annual Meeting of the American Society of Hematology (ASH).

This page offers presentation schedules for our faculty; explainer videos; program and clinical trial information; and more.

Stay current on Twitter: #ASH20

ASH 2020 Oral Presentations by Dana-Farber Faculty

Saturday, December 5
Sunday, December 6
Monday, December 7

Dana-Farber News from ASH 2020

• Dana-Farber presented more than 40 research studies at 2020 ASH Annual Meeting
• Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome (see video below) (read ASCO Post coverage)
• Study revealed surprising benefit of clonal hematopoiesis in allogeneic transplants
• CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma (see video below) (read Healio coverage)
• Venetoclax added to standard treatments showed promise in high-risk myeloid blood cancers (read ASH Clinical News coverage)
• Circulating tumor DNA indicates risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma

Video Highlights

• Dr. Christopher Gibson summarized his team’s study on the impact of donor DNMT3A clonal hematopoiesis for allogeneic hematopoietic cell transplant.
• Dr. Reid Merryman discussed how circulating tumor DNA may indicate relapse after stem cell transplant for patients with diffuse large B-cell lymphoma.
• Dr. Roman Shapiro summarized the results of the first three cases of cytokine-induced memory-like NK cells post-haploidentical stem cell transplantation.
• Dr. Oreofe Odejide highlighted abstract 744 from ASH 2020, which discusses depression and anxiety among patients with hematologic malignancies.
• Dr. Vincent Ho reported on abstract 2371 from ASH 2020, which looks at the real-world experience of defibrotide after hematopoietic stem cell transplant.
• Dr. Andrew Lane highlighted the male-biased spliceosome mutations in blastic plasmacytoid dendritic cell neoplasm as presented at ASH 2020.
• Dr. Marlise Luskin explained the incidence of orthopedic toxicity among adolescents and young adults with ALL that seem to be associated with their treatment regimen.
  
• Dr. Jennifer Crombie gave an update of the clinical trial evaluating duvelisib and venetoclax in patients with relapsed or refractory CLL/SLL or Richter's Syndrome.
• Dr. Annamaria Gullà detailed abstract 665 from ASH 2020 on how bortezomib induces an anti-multiple myeloma response in treatment.

ASH Awards for Dana-Farber Faculty

Edward J. Benz, Jr., MD
ASH Award for Leadership in Promoting Diversity

Annamaria Gullà, MD
2020 Joanne Levy, MD, Memorial Award for Outstanding Achievement
Project title: "Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application"

Elisa ten Hacken
ASH Abstract Achievement Award
ASH Scholar Award

Kirsty Hillier, MD
ASH Research Training Award for Fellows

Peter Miller, MD, PhD
ASH Research Training Award for Fellows

Samuel Ng, MD, PhD
ASH Scholar Fellow to Faculty Award in Basic/Translational Research
Project title: Mechanistic Insight to Target BATF3-IRF4 Transcription Factor Complexes in Peripheral T-cell Lymphoma"

Oreofe Odejide, MD, MPH
ASH Junior Faculty Scholar Award for Clinical Research
Project title: "An Intervention for Fear of Cancer Recurrence Among Lymphoma Survivors"